In a recent press release from Intarcia Therapeutics, Inc. they announced the appointment of four new members to its board of directors. Dr. Patrick Conway, Jim Rosenthal, Dr. Jay Skyler and the Honorable Bob Kerrey will be joining the board. Each of these industry leaders and experts in their fields
Each of these industry leaders and experts in their fields are expected to add significant and sustained value for Intarcia as it continues to develop and advance life-changing therapeutic options to address treatment and prevention outcomes in some of the most devastating and costly chronic diseases around the world. They will also provide knowledgeable counsel and guidance as Intarcia continues to build its novel portfolio of treatment options that can be used with its disruptive Medici Drug Delivery System™, Intarcia’s innovative and proprietary technology platform that was designed to enable therapies to be delivered just once or twice per year.
“Our board has been critical to our success over the years and our newly elected members bring a wealth of new experiences in the healthcare policy, payer landscape, science and global financial sectors. Each Director was carefully selected over the last nine months and comes with a proven track record of leadership and success” said Kurt Graves, Chairman, President and CEO of Intarcia Therapeutics. “The value of their expertise and networks in working with payers, investors, regulatory bodies and policy makers is immeasurable as we continue to focus on delivering our pipeline of disruptive treatments aimed at transforming the way we treat and prevent serious chronic diseases.”.
Patrick Conway, MD: Dr. Patrick Conway just recently became the President and CEO of Blue Cross Blue Shield of North Carolina. Prior to this he served as the Chief Medical Officer, Deputy Administrator for Innovation and Quality and Director of the Center for Medicare & Medicaid Innovation for the Centers of Medicare and Medicaid Services. There, he was responsible for overseeing the quality of care, innovation and new payment models for the programs that serve the over 140 million Americans for access to health care services through Medicare, Medicaid, the Children’s Health Insurance Program, and the Health Insurance Marketplace. The CMS Innovation Center he led had a budget of $10 billion over 10 years. He was instrumental in helping lead the country to these value-based and outcomes-based care systems. He is a former White House Fellow and a Robert Wood Johnson Clinical Scholar. Dr. Conway completed his pediatrics residency at Harvard Medical School's Children's Hospital Boston, graduated with High Honors from Baylor College of Medicine, and graduated summa cum laude from Texas A&M University.
Jim Rosenthal: Jim Rosenthal is the Chief Executive Officer of BlueteamGlobal and a Senior Advisor at Morgan Stanley. Until recently, he served as the company’s Chief Operating Officer after joining the firm nearly a decade ago, where he managed day-to-day operations. Mr. Rosenthal has significant experience across a wide spectrum of financial services. Prior to joining Morgan Stanley, Mr. Rosenthal held positions at Tishman Speyer; Lehman Brothers and McKinsey & Company, where he was a Senior Partner specializing in financial institutions. He is also the Co-Chairman of Sheltered Harbor, a consortium of major banks, securities firms, industry associations and technology service providers with the mission of preserving retail depositor and investor systemic confidence in the event of a cyberattack. Rosenthal currently serves on the Board of Director of HIS Markit, OnDeck and Hyperloop. Rosenthal has a B.A. degree from Yale University and a J.D. degree from Harvard Law School.
Jay S. Skyler, MD, MACP: Dr. Jay Skyler currently serves as a Professor of Medicine, Pediatrics and Psychology in the Division of Endocrinology Diabetes & Metabolism at the Leonard M. Miller School of Medicine at the University of Miami, where he has also held a number of key leadership roles in the clinical and drug development setting. He has played a key global leadership role in advancing the science and treatments of diabetes over the last five decades, where his own research has also focused on improving the care of type 1 diabetes through meticulous glycemic control, psychosocial and behavioral support and immune intervention. From 1993 until 2015, he was Chairman of the National Institute of Health-sponsored Diabetes Prevention Trial - Type 1 (DPT-1) and its successor Type 1 Diabetes TrialNet, a nationwide network conducting clinical trials to interdict type 1 diabetes. Dr. Skyler has also held many positions at the American Diabetes Association (ADA), including President and member of the Board of Directors. He was founding Editor-in-Chief of Diabetes Care (an ADA publication), founding Scientific Editor of the International Diabetes Monitor, and currently is Senior Editor of Diabetes Technology & Therapeutics. He has served on the Board of Directors for multiple private and public companies including MiniMed, Amylin, Dexcom, Inc. DXCM and Moerae Matrix, Dr. Skyler has been author, editor, or co-editor of 21 books and has written nearly 500 articles. Dr. Skyler is a graduate of Pennsylvania State University and Jefferson Medical College, and did his postgraduate training in internal medicine and in endocrinology & metabolism at Duke University Medical Center.
The Honorable Bob Kerrey: Former Senator Bob Kerrey, who represented Nebraska as a United States Senator from 1989-2001 and as its 35th governor, serves as the managing director at Allen & Company, a small investment banking firm in New York City. He is also the executive chairman of the Minerva Project, a for-profit educational organization that provides technology, infrastructure and support services for the Minerva Schools and Keck Graduate Institute. Previously for 10 years, Kerrey served as the President of The New School, a small private university in New York City, during which the university doubled its endowment and experienced growth in enrollment, faculty, scholarship funding, capital projects, research and international engagement. Since concluding his service as a Senator, he continues to serve on key committees including the 9/11 Commission as well as the Iraq and Afghanistan Veterans Association. Kerrey served three years as a Navy SEAL in the U.S. Navy and is a Medal of Honor recipient. He earned his B.S. in Pharmacy from the University of Nebraska.
“On behalf of Intarcia, its Board of Directors and shareholders, I would like to genuinely extend our collective gratitude to Dr. Irwin Scher, Glen Sato and Dr. Emad Rizk for their tenure as members of our Board,” added Graves. “Their invaluable insights and contributions have helped us grow Intarcia into an entity with a bright future full of promise for the treatment and prevention of serious chronic diseases”.
For more information about Intarcia’s newest board members, please visit our website.
About Intarcia Therapeutics, Inc.
Intarcia Therapeutics, Inc. is a biopharmaceutical company developing therapies to enhance treatment and prevention outcomes by optimizing and improving the efficacy, continuous administration and tolerability of drug therapies. Delivering medicines just once- or twice yearly to prevent and/or chronically treat diseases holds potential to improve outcomes by improving effectiveness over time and by addressing real-world unmet needs around poor patient adherence and persistence rates that are high in the majority of chronic diseases. Intarcia is investigating multiple therapies, including combination therapies, for chronic diseases leveraging the convergence of novel medicines and the proprietary Medici Drug Delivery System™. Intarcia is developing a strong pipeline in important therapeutic areas, including: diabetes, obesity, autoimmune diseases, HIV, and other serious disorders.
News from our partners.